HTG2014-Section-Header-publications

2019

The Anti-CD25 Antibody-Drug conjugate Camidanlumab Tesirine (ADCT-301) Presents a Strong Preclinical Activity both as Single Agent and in Combination in Lymphoma Cell Lines

Spriano, F. et al. The Anti-CD25 Antibody-Drug Conjugate Camidanlumab Tesirine (ADCT-301) Presents a Strong Preclinical Activity Both as Single Agent and in Combination in Lymphoma Cell Lines. Poster presented at: 15th International Conference on Malignant Lymphoma Palazzo dei Congressi; 2019 Jun 18-22; Lugano, Switzerland.  Hematological Oncology VOL 37, Issue S2. https://doi.org/10.1002/hon.134_2630

Download pdf 2.4MB
View External Link

Page last updated September 16, 2021